AIM ImmunoTech (NYSE:AIM) Price Target Cut to $1.00

AIM ImmunoTech (NYSE:AIM) had its price objective lowered by Maxim Group from $2.00 to $1.00 in a report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

AIM ImmunoTech Price Performance

Shares of AIM opened at $0.26 on Tuesday. The stock’s 50-day moving average price is $0.30 and its two-hundred day moving average price is $0.36. AIM ImmunoTech has a 12 month low of $0.21 and a 12 month high of $0.62. The company has a market capitalization of $13.41 million, a PE ratio of -0.41 and a beta of -0.39. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.05.

AIM ImmunoTech (NYSE:AIM) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.05 million during the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. On average, analysts anticipate that AIM ImmunoTech will post -0.35 EPS for the current year.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC acquired a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is owned by institutional investors and hedge funds.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).